On World Rare Disease Day, our team stands together to show support for those who suffer from rare diseases. For the past ten years, our company has been conducting research on three new therapeutic solutions to improve the lives of rare disease patients.
The first project involves developing an AI platform-based treatment for systemic sclerosis in collaboration with Oncocross, a Korea-based AI tech company.
The second project is a partnership with Delta 4, an AI tech company based in Vienna, Austria, to discover and develop a drug candidate for treating Primary Sclerosis Cholangitis, a rare autoimmune chronic liver disease.
The third project is centered around 4P020, a beta-3 adrenergic receptor agonist developed as a first-in-class therapeutic drug for Stargardt disease.We are working on this project in collaboration with the Institute de la Vision and SATT Lutech.
We are proud to support World Rare Disease Day and we aim is to bring new treatments to improve the quality of life for those who suffer from these conditions.
